PlexusDx prioritizes 503A compounders because the direct-to-patient model ensures traceability, quality control, and regulatory transparency
A recent International Foundation of Employee Benefit Plans survey shows that while employers are open to covering GLP-1 drugs for diabetes, theyre far more hesitant to do so for weight loss
The article names uncontrolled diabetes, a history of pancreatitis, and kidney disease as conditions requiring close monitoring even during routine dosing, and by extension during any interruption
Review important medication safety information
Lower production costs can lower the price of drugs, making treatment more affordable for more patients
As a citizen of the world, Debapriya has been fascinated by the lives of people across the globe throughout time